A new study shows that the use of the P110 (an inhibitor of Drp1-Fis1 interaction) to inhibit Drp1 hyperactivation is adequate to mitigate HD-associated behavioral impairments and neuropathology (Zhao et al., 2018). Here, DNM1L is linked to Huntington disease.